Lunai Bioworks Inc.

NASDAQ: LNAI · Healthcare · Biotechnology

PublicHQ Los Angeles, CA · Los AngelesCIK 0001527728Reports USD

#1161 of 1,418 Healthcare companies by revenue

EA Score

20D

FH 25DQ 11GM —SS 31

v0.1 · 55/100 weight · provisional

↑ Piotroski F, market scale · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

$20.9k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$178.0M

Employees

as of 2026-08-22

Market cap

$9.8M

as of 2026-08-22

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02011

Net income-$178.0M-$178.0M2025

Operating income-$189.0M-$189.0M2025

Total assets$8.2M$8.2M2025

Liabilities$29.6M$29.6M2025

Equity-$21.3M-$21.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Lunai Bioworks Inc.’s revenue?

Lunai Bioworks Inc. booked $0 in FY2011 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Hemostemix Inc——Integrated Cannabis Solutions, Inc.——Theriva Biologics, Inc.39D GT Biopharma, Inc.32D PreveCeutical Medical Inc.——Revive Therapeutics Ltd.——

Neighbors

Los Angeles →

The Walt Disney Company$94.4B72B Public Storage$4.8B80B+Southern California Gas Company PFD SER A 6%——Ares Management Corporation$5.6B68B Live Nation Entertainment, Inc.$25.2B76B+Rocket Lab USA, Inc.$601.8M50D

Key facts

CEODavid H. Weinstein

SectorHealthcare

IndustryBiotechnology

HeadquartersLos Angeles, CA

ExchangeNASDAQ: LNAI

Employees29

IPO date2025-09-30

Latest filings

8-K2026-06-17 8-K2026-06-16 8-K2026-05-20 10-Q2026-05-15 8-K2026-05-13 8-K2026-05-01 8-K2026-04-28 DEF 14A2026-04-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.